metaEvidence - overview

button bars forest bayes pooled summary circles


			deaths (OS)
laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1)
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	1	0.83 [0.70; 0.99], 1 RCT, I2=0% unassessable degree of certainty
	pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU	1	0.77 [0.63; 0.94], 1 RCT, I2=0% conclusive unassessable degree of certainty
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	2	0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty
	pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU	2	0.63 [0.51; 0.77], 1 RCT, I2=0% conclusive unassessable degree of certainty
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	0.80 [0.65; 0.98], 1 RCT, I2=0% conclusive unassessable degree of certainty
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	0.74 [0.58; 0.94], 1 RCT, I2=0% conclusive unassessable degree of certainty